Kakimoto Naoya, Inoue Takehiro, Inoue Toshihiko, Murakami Shumei, Furukawa Souhei, Yoshida Ken, Yoshioka Yasuo, Yamazaki Hideya, Tanaka Eiichi, Shimizutani Kimishige
Department of Oral and Maxillofacial Radiology, Division of Oral Developmental Biology, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan.
Radiother Oncol. 2003 Aug;68(2):123-8. doi: 10.1016/s0167-8140(03)00055-0.
To evaluate the treatment results of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (ISBT) for T3 mobile tongue cancer.
Between 1974 and 1992, 61 patients with T3 mobile tongue cancer were treated with LDR ISBT using (192)Ir hairpins with or without single pins. In addition, between 1991 and 1999, 14 patients were treated with HDR ISBT. For nine patients treated with ISBT alone, the total dose was 59-94 Gy (median 72 Gy) within one week in LDR ISBT and 60 Gy/10 fractions/5 days in HDR ISBT. For 66 patients treated with a combination therapy of external beam radiotherapy (EBRT) and ISBT, the total dose was 12.5-60 Gy (median 30 Gy) of EBRT and 50-112 Gy (median 68 Gy) within 1 week in LDR ISBT or 32-60 Gy (median 48 Gy)/8-10 fractions/5-7 days in HDR ISBT.
The 2- and 3-year local control rates of all patients were both 68%. The 2- and 3-year local control rates of patients treated with LDR ISBT were both 67%, and those with HDR ISBT were both 71%. The local control rate of patients treated with HDR ISBT was similar to those with LDR ISBT.
ISBT for T3 mobile tongue cancer is effective and acceptable. The treatment result of HDR ISBT is almost similar to that of LDR ISBT for T3 mobile tongue cancer.
评估低剂量率（LDR）和高剂量率（HDR）组织间近距离放射治疗（ISBT）对T3期活动期舌癌的治疗效果。
1974年至1992年间，61例T3期活动期舌癌患者接受了使用（192）Ir发夹状施源器加或不加单针的LDR ISBT治疗。此外，1991年至1999年间，14例患者接受了HDR ISBT治疗。对于仅接受ISBT治疗的9例患者，LDR ISBT在1周内的总剂量为59 - 94 Gy（中位剂量72 Gy），HDR ISBT为60 Gy分10次在5天内给予。对于66例接受外照射放疗（EBRT）与ISBT联合治疗的患者，EBRT的总剂量为12.5 - 60 Gy（中位剂量30 Gy），LDR ISBT在1周内的剂量为50 - 112 Gy（中位剂量68 Gy），或HDR ISBT为32 - 60 Gy（中位剂量48 Gy）分8 - 10次在5 - 7天内给予。
所有患者的2年和3年局部控制率均为68%。接受LDR ISBT治疗患者的2年和3年局部控制率均为67%，接受HDR ISBT治疗患者的均为71%。接受HDR ISBT治疗患者的局部控制率与接受LDR ISBT治疗患者的相似。
ISBT治疗T3期活动期舌癌有效且可接受。HDR ISBT对T3期活动期舌癌的治疗效果与LDR ISBT几乎相似。
